Zoetis Inc (ZTS) Expected to Post Quarterly Sales of $1.33 Billion
Brokerages expect that Zoetis Inc (NYSE:ZTS) will announce sales of $1.33 billion for the current quarter, according to Zacks. Three analysts have made estimates for Zoetis’ earnings. The lowest sales estimate is $1.31 billion and the highest is $1.35 billion. Zoetis reported sales of $1.23 billion in the same quarter last year, which indicates a positive year over year growth rate of 8.1%. The company is scheduled to report its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Zoetis will report full-year sales of $1.33 billion for the current financial year, with estimates ranging from $5.68 billion to $5.77 billion. For the next year, analysts forecast that the business will report sales of $6.03 billion per share, with estimates ranging from $5.90 billion to $6.10 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Zoetis.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.47 earnings per share.
In other news, EVP Roxanne Lagano sold 35,663 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now owns 49,919 shares in the company, valued at approximately $4,044,437.38. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total transaction of $3,034,442.06. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.
Several institutional investors have recently modified their holdings of ZTS. Polen Capital Management LLC purchased a new stake in Zoetis in the 4th quarter valued at $285,967,000. Bessemer Group Inc. raised its position in Zoetis by 231,590.8% in the 4th quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock valued at $152,557,000 after purchasing an additional 2,116,740 shares during the last quarter. BlackRock Inc. raised its position in Zoetis by 3.8% in the 4th quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock valued at $2,772,498,000 after purchasing an additional 1,394,156 shares during the last quarter. Millennium Management LLC raised its position in Zoetis by 208.1% in the 4th quarter. Millennium Management LLC now owns 1,984,470 shares of the company’s stock valued at $142,961,000 after purchasing an additional 1,340,378 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Zoetis by 111.3% in the 4th quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock valued at $123,143,000 after purchasing an additional 900,261 shares during the last quarter. Institutional investors and hedge funds own 94.18% of the company’s stock.
Shares of Zoetis (NYSE ZTS) traded up $2.03 during mid-day trading on Tuesday, hitting $82.79. 2,662,714 shares of the company were exchanged, compared to its average volume of 3,080,078. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77. The firm has a market capitalization of $39,980.00, a PE ratio of 37.98, a P/E/G ratio of 1.81 and a beta of 1.07. Zoetis has a 52-week low of $52.25 and a 52-week high of $82.93.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Thursday, April 19th. Zoetis’s payout ratio is 22.94%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.